Delivery Order SPE2DB20D2104-SPE2DB22FR83Y
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,271.54, is for the delivery of Xifaxan 550 mg tablets. The contract has a period of performance through November 20, 2024 and utilizes a firm fixed price pricing structure. This award is a delivery order under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply the drug Xifaxan 550 mg tablets. The delivery order has a firm fixed price of $2,666.97 and a completion date of June 6, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025, which enables the DLA to efficiently...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
- This federal contract award, valued at $12,938.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,691.88, is for the delivery of Xifaxan 550 mg tablets. This is a Delivery Order contract with a Firm Fixed Price pricing type, with a completion date of December 6, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a division of the Amerisourcebergen Corporation, for the provision of pharmaceutical products and medical supplies. The award, valued at $6,176.87, is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical. This single-award IDC, worth up to $999,999,999.00 through December 31, 2025, serves as the primary vehicle for...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of Xifaxan 550 mg tablets. The contract has a ceiling value of $4,050.50 and is a firm fixed price delivery order with a completion date of November 14, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award is for the pharmaceutical product Xifaxan 550 mg tablets, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $10,969.73, was awarded by the Defense Logistics Agency (DLA) as a delivery order. It has a firm fixed price and an ultimate completion date of March 28, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery...
- This federal contract award is for the delivery of Xifaxan 550 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $43,509.79, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by the parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2025. This IDC serves as the...
- This federal contract award, valued at $27,156.27, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a specialty pharmaceutical product. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999.00...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR83YDelivery Order
This federal contract award, valued at $56,703.88, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Xifaxan 550 mg tablets, a specialty pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical medical commodities, to support military healthcare programs globally. The contract was awarded through full and open competition without any set-aside designations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.7k | 2/15/22 |